CombiGene AB (COMBI) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 48 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

333.33%

Debt Equity

-1.09

Return on Equity

-81.18%

Price to Book

0.86

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2024)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-2.87%

6 Months

-10.9%

1 Year

-27.74%

2 Years

-65.95%

3 Years

-70.02%

4 Years

-69.62%

5 Years

-86.41%

CombiGene AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.87%

EBIT Growth (5y)

-34.35%

EBIT to Interest (avg)

-24.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.06

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

20.96%

ROE (avg)

6.13%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.90

EV to EBIT

0.23

EV to EBITDA

0.32

EV to Capital Employed

2.15

EV to Sales

-10.78

PEG Ratio

Dividend Yield

320.00%

ROCE (Latest)

942.46%

ROE (Latest)

-81.18%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -57.78% vs -18.42% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.90",
          "val2": "-6.50",
          "chgp": "9.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.20",
          "val2": "-9.00",
          "chgp": "-57.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -94.55% vs -79.40% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -25.77% vs -475.81% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "5.50",
          "chgp": "-94.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.80",
          "val2": "-36.20",
          "chgp": "6.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.90",
          "val2": "-2.30",
          "chgp": "-373.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.90",
          "val2": "-35.70",
          "chgp": "-25.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-110,184.40%",
          "val2": "-6,581.40%",
          "chgp": "-10,360.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ

Dec'24

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.90

-6.50

9.23%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.20

-9.00

-57.78%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is -57.78% vs -18.42% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.30

5.50

-94.55%

Operating Profit (PBDIT) excl Other Income

-33.80

-36.20

6.63%

Interest

0.00

Exceptional Items

-10.90

-2.30

-373.91%

Consolidate Net Profit

-44.90

-35.70

-25.77%

Operating Profit Margin (Excl OI)

-110,184.40%

-6,581.40%

-10,360.30%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -94.55% vs -79.40% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -25.77% vs -475.81% in Dec 2023

All Annual Results

Company CV

About CombiGene AB

CombiGene AB

Pharmaceuticals & Biotechnology

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Company Coordinates

Company Details

Medicon Village, Scheelevagen 2 , LUND None : 223 81

Tel: 46 40 6718906

http://combigene.com/

Registrar Details